ESR1 and neoplasm: A similar study analyzing proteomes of 102 paraffin-embedded breast tumor samples, which were classified either as estrogen receptor (ER)+/progesterone receptor (PR)+or triple-negative, revealed that some of the ER+/PR+tumor samples shared expression profiles with those of triple-negative cases [58].